undamentalytics Newsletter
Sign in

Entera Bio Ltd. (ENTX) stock

Add to watchlist

Add holding +

NASDAQ: ENTX Nasdaq Biotechnology Next results ~November 13, 2026

Entera Bio Ltd. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

Not valued: the figures our models need are missing or failed our data-quality checks.

Price vs value

No model value: limited reported history: available models are shown without a Buy/Hold/Sell rating. How we value companies.

Entera Bio Ltd. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders5 buying, 0 selling8 purchases and 0 sales by directors and officers, last 12 monthsInsider trades
  • Funds15 adding, 12 cuttingOf 5 active managers that changed their stake, 1 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Next results ~November 13, 2026 (estimated)

Current signal Results well short of expectations: Reported earnings per share missed the analysts' consensus estimate by 75% in the quarter to 2026-06-30.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Entera Bio Ltd.'s latest figures clears our strength thresholds.

Things to watch

  • Results due soon. Results are expected around 13 November; the share price can move sharply on the day.
  • Volatile shares. Over the past year the shares showed annualised volatility of 127% and a beta of 0.8 against the S&P 500.

Latest results

Earnings per share
-$0.14 against an average estimate of -$0.08: missed by 75.0%
Share reaction
+7.8% in the first session after the results on August 7, 2026, against +0.6% for the S&P 500
Next report
November 13, 2026

Entera Bio's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-3.4%
  • 1 week+8.0%
  • 1 month+8.0%
  • This year+59.3%
  • 1 year+6.2%
  • 5 years-27.0%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Earnings

Last results
August 7, 2026
Next results (est.)
November 13, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Leadership
  2. Leadership
  3. Announcement
  4. Results
  5. Leadership
  6. Leadership

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Entera Bio Ltd. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Valuation models

We value Entera Bio Ltd. as an operating company, with every model that fits that kind of business. Cost of equity 8.5%: the 10-year Treasury yield (4.9%) plus a beta of 0.79 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no twelve-month earnings or share count in the filings yet
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: no twelve-month earnings or share count in the filings yet
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: no twelve-month earnings or share count in the filings yet
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. — Does not apply: no twelve-month earnings or share count in the filings yet
Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. — No model applies: the filings don’t yet support a value.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Entera Bio Ltd. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 13, 2026, after the close. Analysts expect revenue of $0 for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.40 −61% — −100%
Next −$0.42 −5% — 0%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +18.2% on 90 days ago. In the last 30 days, 0 analysts raised Entera Bio Ltd.'s forecast and 0 cut it.

Consensus EPS forecast Entera Bio Ltd., last 90 days
−$0.60 −$0.40 −$0.20 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.34 Current fiscal year, 60 days ago: −$0.34 Current fiscal year, 30 days ago: −$0.34 Current fiscal year, 7 days ago: −$0.40 Current fiscal year, Now: −$0.40 −$0.40 Next fiscal year, 90 days ago: −$0.57 Next fiscal year, 60 days ago: −$0.57 Next fiscal year, 30 days ago: −$0.57 Next fiscal year, 7 days ago: −$0.42 Next fiscal year, Now: −$0.42 −$0.42

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$0.34−$0.57
60 days ago −$0.34−$0.57
30 days ago −$0.34−$0.57
7 days ago −$0.40−$0.42
Now −$0.40−$0.42

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.08 −$0.14 −75.0%
Mar 2026 −$0.08 −$0.07 +12.5%
Dec 2025 −$0.09 −$0.06 +33.3%
Sept 2025 −$0.09 −$0.07 +22.2%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

5 analysts, Oct 2026
Buy5100%
Hold00%
Sell00%

Monthly trend

  1. Oct 202655
  2. Sep 202655

Counts of recommendations published by analysts covering Entera Bio Ltd., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
3.3%
of tradable shares
Days to cover
9.01
at average volume
Short interest, 1 month
+333%
to October 15, 2026
Held by institutions
34%
of shares
Held by insiders
5.4%
of shares
Employees
20
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
ENTX+161%−74%−18%+253%−9%+59%
Industry peers (median)−36%−56%−17%−29%−5%−27%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
ENTX33%25%50%67%42%55%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
ENTX−59%−85%−62%−50%−45%−49%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since June 28, 2018: 93% from March 12, 2021 to November 11, 2022. Getting back needed a 1280% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$1.00 – $3.92
From 52-week high
−21.2%
vs 50-day average
+6.8%
vs 200-day average
+61.4%
Volatility (1 year)
127%
Beta vs S&P 500
0.81

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
3 up, 9 down
typical move ±4.9%
After a week
5 up, 7 down
typical move ±6.8%
After a month
7 up, 5 down
typical move ±17.3%
Results releasedNext dayS&P 500 next day5 days21 days
August 7, 2026 +7.8% +0.6% +2.5% +6.7%
May 8, 2026 −14.6% +1.1% −8.0% −10.9%
March 27, 2026 −2.9% −2.0% +15.5% +9.7%
November 14, 2025 −2.2% −0.9% −7.7% −23.7%
August 8, 2025 +4.4% +0.6% +11.1% +3.3%
May 9, 2025 −3.2% +3.2% −8.6% −4.3%
March 28, 2025 −5.3% −1.4% −10.9% +24.2%
November 8, 2024 −2.9% +0.5% −1.1% +30.9%
August 9, 2024 −2.7% +0.5% +1.6% +16.0%
May 10, 2024 −7.9% +0.1% −3.9% −17.7%
March 8, 2024 0.0% −0.7% −6.2% +54.1%
November 14, 2023 +4.3% +2.2% +4.3% −6.3%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms . Generated November 3, 2026. Definitions in our methodology.

Who owns it

Funds buying and selling
Reported value
$19M
Institutions reporting
27
Shares held vs prior quarter
▲ 36.3%
Positions opened / closed
7 / 6

Top buyers and sellers, Q2 2026: 15 institutions bought and 12 sold ; the biggest buyer was Bvf Inc (+2.4M shares) and the biggest seller Citadel Advisors LLC (−207K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Knoll Capital Management, LLC $10.4M 5.9M 54.8% 0.0%
Bvf Inc $4.3M 2.4M 22.6% New
Siren, L.L.C. $1.3M 736K 6.9% New
Renaissance Technologies LLC $652,859 369K 3.4% ▼ 22.1%
Parkman Healthcare Partners LLC $485,860 274K 2.6% ▼ 4.9%
PNC Financial Services Group, Inc. $483,265 273K 2.5% ▲ 2630.3%
Seven Fleet Capital Management LP $338,697 191K 1.8% ▼ 6.9%
Hightower Advisors, LLC $132,935 75K 0.7% ▲ 102.5%
HRT Financial LP $128,000 72K 0.7% ▲ 367.9%
Schonfeld Strategic Advisors LLC $104,201 59K 0.5% ▲ 6.6%
Two Sigma Securities, LLC $86,010 49K 0.5% New
Signature Estate & Investment Advisors LLC $83,771 47K 0.4% 0.0%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Entera Bio Ltd.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $140,880 8 trades by 5 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $140,880 net buying
Insider Date Trade Shares Price Value
Germano Geno J Director March 9, 2026 Buy 20,000 $1.30 $26,000
Ellis Sean Director March 5, 2026 Buy 10,000 $1.23 $12,300
Rubin Steven D Director February 12, 2026 Buy 5,000 $1.49 $7,450
Germano Geno J Director February 10, 2026 Buy 20,000 $1.49 $29,800
Taitel Haya Director February 10, 2026 Buy 7,500 $1.48 $11,100
Ellis Sean Director February 9, 2026 Buy 18,000 $1.24 $22,320
Rubin Steven D Director February 9, 2026 Buy 10,000 $1.20 $12,000
Toledano Miranda Jayne Chief Executive Officer December 29, 2025 Buy 11,000 $1.81 $19,910

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 13, 2026 estimated from the company's past filing pattern, not announced

  • August 7, 2026
  • May 8, 2026
  • March 27, 2026
  • November 14, 2025
  • August 8, 2025
  • May 9, 2025

Recent SEC filings

Data status

When each part of this page on Entera Bio Ltd. was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Entera Bio Ltd. in brief

What does Entera Bio Ltd. do?
Entera Bio Ltd. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Entera Bio Ltd.'s stock ticker?
Entera Bio Ltd. trades under the ticker ENTX on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Entera Bio Ltd.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Knoll Capital Management, LLC, Bvf Inc and Siren, L.L.C. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Are insiders buying or selling Entera Bio Ltd. stock?
Over the last 12 months, Entera Bio Ltd.'s directors and officers reported 8 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.
When is Entera Bio Ltd.'s next earnings date?
Around November 13, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Entera Bio Ltd. announces its own schedule.